Compare Merck & Co., Inc. (MRK) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Waste Management, Inc. — how do they compare? Merck & Co., Inc. trades at $148.18 (market cap $366.28B), while Waste Management, Inc. trades at $217.1 (market cap $87.05B). The key difference: Merck & Co., Inc. is far larger — about 4.2× Waste Management, Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| MRK | WM | |
|---|---|---|
Market Cap | $366.28B | $87.05B |
Sector | Health | Industrials |
52-Week High | $156.43 | $246.51 |
52-Week Low | $77.60 | $196.77 |
Enterprise Value | $413.04B | $109.85B |
Dividend Yield | 2.29% | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
WM trades at $217.78, down 0.55% on the day, with a bearish technical signal from moving averages. The company reported mixed Q2 2026 earnings, beating EPS estimates but missing Q4 2025. Revenue grew to $25.20B in 2025, with strong profitability margins. Analysts maintain a buy consensus with a $263.43 price target, though technical indicators show near-term pressure.
The outlook is supported by steady waste-service demand and sustainability investments, but high debt levels and valuation concerns pose risks. CEO transition adds uncertainty, while institutional buying signals confidence. Upside exists if execution aligns with analyst targets, but investors should weigh premium valuation against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
